tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
Derek Jellinek

Derek Jellinek

ABN Amro
Wall Street Analyst
Ranked #5,199 out of 8,045 Analysts on TipRanks (#12,990 out of 21,519 overall experts)

Success Rate

60%
3 out of 5 Profitable Transactions

Average Return

0.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Derek Jellinek's ratings since 2009 and opened each position for the duration of 1 Year:
60.00% of your transactions would have been profitable with an average return of 0.4%

Stock Rating Distribution

75Ratings
65.33% Hold
34.67% Buy
0.00% Sell
Distribution of Derek Jellinek's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
AustraliaAustralian Market

Best Rating

Stock:
CSL Limited
(CMXHF)
Rating Type:Buy
Dates:Feb 17, 2022 - Jan 01, 1970
Gain:5.60%
The most profitable rating made by Derek Jellinek

Derek Jellinek's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
~ARRY
Array Biopharma
Dec 15, 2009
Hold
Reiterated
0.00%
1
Jun 25, 2019
Hold
Reiterated
0.00%
1
Ansell
Feb 16, 2022
Hold
Reiterated
$19.61
(12.30% Upside)
0.00%
10
Feb 17, 2022
Buy
Reiterated
$233.33
(14.10% Upside)
50%
+0.45%
13
Sonic Healthcare Limited
Feb 22, 2022
Hold
Downgraded
A$39.93
(18.91% Upside)
0.00%
15
Cochlear Limited
Feb 23, 2022
Buy
Upgraded
$166.09
(10.27% Upside)
100%
+0.60%
9
PHCRF
Healius Limited
Feb 24, 2022
Buy
Reiterated
0.00%
13
Ramsay Health Care
Feb 25, 2022
Hold
Reiterated
$48.21
(0.49% Upside)
0.00%
13
List of latest recommendations made by Derek Jellinek. Click to expand and see Derek Jellinek's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More